TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update

Publication

TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update

Journal Paper/Review - Jul 31, 2020

Vulliemoz Marianne, Brand Stephan, Juillerat Pascal, Mottet Christian, Ben-Horin Shomron, Michetti Pierre, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology

Citation

Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. Digestion 2020; 101 Suppl 1:16-26.

Type

Journal Paper/Review (English)

Journal

Digestion 2020; 101 Suppl 1

Publication Date

Jul 31, 2020

Issn Electronic

1421-9867

Pages

16-26

Brief description/objective

BACKGROUND
Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years.

SUMMARY
This review article aimed to provide an update on recent advances in TNF antagonist therapy for IBDs. Key Messages: Their position in the treatment algorithm has evolved to "rapid step-up therapy" or "top-down therapy" according to disease severity and patients' characteristics. Limitations of anti-TNF antagonists include loss of response in up to 30-50% of patients with or without the development of antibodies. Therapeutic drug monitoring should provide a tailored, personalized approach to this scenario. Recently, biosimilar agents have been approved for IBDs and are considered equivalent in efficacy to the originator.